5HZ1.F HANGZHOU TIGERMED CO. H 1

Healthcare Biotechnology Frankfurt Exchange
30.14 EUR
Close of Nov 11, 2026
3.20 5.87
Market cap
EUR 3.71B
P/E
-
P/B
1.41x
ROE
-1.8%
Dividend yield
0.37%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 5HZ1.F undervalued?

Graham number

The Graham number of HANGZHOU TIGERMED CO. H 1 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

HANGZHOU TIGERMED CO. H 1 fundamental analysis

No fundamental analysis for HANGZHOU TIGERMED CO. H 1 yet.

HANGZHOU TIGERMED CO. H 1 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About HANGZHOU TIGERMED CO. H 1

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as …

Full company profile